Latest revenue
$0
as of 2026-01-31
Latest net income
$-4.3M
as of 2026-01-31
Net margin
—
as of 2026-01-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $14.3M
- Enterprise value
- $14.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $5.04
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 41.0M
5-year trend
What this company does
Company Overview Quantumzyme Corp., is a biotransformation company, focused on clean and green chemistry. Specifically, Quantumzyme is in the business of developing engineered enzymes in the application of active pharmaceutical ingredients (“API”) production. As we move forward, we intend to expand beyond the API marketplace and engineer enzymes for the use and deployment in other business sectors such as fragrance and flavors, climate impacting applications like sustainable materials, plastic degradation and carbon capture. In the development and engineering of enzymes, we conduct research to enhance enzyme activity, selectivity, and specificity by applying novel quantum mechanics,…
AI summary unavailable — showing raw filing excerpt
Generated from QTZM's filing dated 2025-11-13
Key risks
RISK FACTORS Please consider the following risk factors and other information in this Registration Statement relating to our business and prospects before deciding to invest in our Shares. This Registration Statement and any investment in our Shares involve a high degree of risk. You should carefully consider the risks described below and all of the information contained in this Registration Statement before deciding whether to purchase our Shares. If any of the following risks actually occur, our business, financial condition and results of operations could be harmed, and you may lose all or part of your investment. The Company should be viewed as a high-risk investment and speculative in…
AI summary unavailable — showing raw filing excerpt
Generated from QTZM's filing dated 2025-11-13
Profitability
Return on equity
45.2%
28.3%Return on assets
-34121.4%
1810.8%Leverage
Debt / equity
-1.00×
3.3%Debt / assets
75565.2%
2476.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-01-31 | $0 | — | $-4.3M | -14426.1% | — |
Q4 2025 2025-10-31 | $0 | — | $-49.9K | +23.9% | — |
Q3 2025 2025-07-31 | $0 | — | $-38.2K | — | — |
Q2 2025 2025-04-30 | $0 | — | $-65.8K | -3.0% | — |
Q1 2025 2025-01-31 | $0 | — | $-29.8K | — | — |
Q4 2024 2024-10-31 | $0 | — | $-65.5K | — | — |
Q2 2024 2024-04-30 | $0 | — | $-63.9K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Industrial Organic Chemicals · SIC 2860
Your notes
Keep private notes on QTZM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for QTZM in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns QTZM
No institutional holdings on file for QTZM yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once QTZM's latest filing finishes processing.